(Q35049433)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12537778%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

review article

1 reference

title

GnRH antagonists: do they open new pathways to safer treatment in assisted reproductive techniques? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12537778%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

author name string

F Olivennes

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12537778%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

publication date

1 January 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12537778%20AND%20SRC:MED&resulttype=core&format=json

Reproductive BioMedicine Online

17 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12537778%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

volume

5 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12537778%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

page(s)

20-25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12537778%20AND%20SRC:MED&resulttype=core&format=json

GnRH antagonist in assisted reproduction: a Cochrane review

17 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Ovarian hyporesponsiveness in combined gonadotropin-releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

The role of LHRH agonists and antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Natural cycles for in-vitro fertilization: cost-effectiveness analysis and factors influencing outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Time to revolutionize ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

A randomized study comparing IVF in the unstimulated cycle with IVF following clomiphene citrate

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Follicular arrest during the midfollicular phase of the menstrual cycle: a gonadotropin-releasing hormone antagonist imposed follicular-follicular transition

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

In vitro fertilization in the natural cycle

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Improved pregnancy outcome with gonadotropin releasing hormone agonist (GnRH-a) stimulation is due to the improvement in oocyte quantity rather than quality

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Safety aspects of gonadotrophin-releasing hormone antagonists in ovarian stimulation procedures: ovarian hyperstimulation syndrome and health of children born.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Cumulative conception and live birth rates in natural (unstimulated) IVF cycles

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Friendly IVF: the way of the future?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

The use of GnRH antagonists in ovarian stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

Biochemical and functional aspects of gonadotrophin-releasing hormone and gonadotrophins

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2811%2960213-7

7 January 2021

10.1016/S1472-6483(11)60213-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12537778%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

1 reference